{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T12:13:36Z","timestamp":1718972016789},"reference-count":29,"publisher":"Danish Medical Association","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ugeskr L\u00e6ger"],"abstract":"<jats:p>Evidence suggests that available antiemetics are equal to intravenous fluid treatment against acute nausea of other causes than motion sickness, pregnancy, anaesthesia, chemo- or radiation therapy. Each antiemetic is associated with adverse effects, which include movement disorders, sedation, and QT prolongation. Intravenous fluid and treatment directed against underlying pathology is recommended as a first-line treatment against nausea in these patients. If an antiemetic is clinically warranted, ondansetron has the most favourable ratio between side effects and price, as argued in this review.<\/jats:p>","DOI":"10.61409\/v11230735","type":"journal-article","created":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T10:38:42Z","timestamp":1713177522000},"page":"1-9","source":"Crossref","is-referenced-by-count":0,"title":["Treatment of nausea in hospitalized patients with acute illness"],"prefix":"10.61409","volume":"186","author":[{"given":"Mariam","family":"Nersesjan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon Carstensen","family":"Nersesjan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikkel Bring","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"40208","published-online":{"date-parts":[[2024,4,15]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Singh P, Yoon SS, Kuo B. Nausea: a review of pathophysiology and therapeutics. Ther Adv Gastroenterol. 2016;9(1):98-112. doi: 10.1177\/1756283X15618131. Doi: https:\/\/doi.org\/10.1177\/1756283X15618131","DOI":"10.1177\/1756283X15618131"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Furyk JS, Meek RA, Egerton-Warburton D. Drugs for the treatment of nausea and vomiting in adults in the emergency department setting. Cochrane Database Syst Rev. 2015;2015(9):CD010106. doi: https:\/\/doi.org\/10.1002\/14651858.CD010106.pub2","DOI":"10.1002\/14651858.CD010106.pub2"},{"key":"ref2","unstructured":"Dansk Selskab for Obstetrik og Gyn\u00e6kologi. Hyperemesis gravidarum. National behandlingsvejledning, 2021. www.dsog.dk\/obstetrik (feb 2024)."},{"key":"ref3","unstructured":"Dansk Selskab for An\u00e6stesi og Intensiv Medicin. Vejledning i forebyggelse og behandling af postoperativ kvalme og opkastning. Dansk Selskab for An\u00e6stesi og Intensiv Medicin, 2021."},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"McKenzie E, Zaki P, Raman S et al. Radiation-induced nausea and vomiting: a comparison between MASCC\/ESMO, ASCO, and NCCN antiemetic guidelines. Support Care Cancer. 2019;27(3):783-791. https:\/\/doi.org\/10.1007\/s00520-018-4586-2","DOI":"10.1007\/s00520-018-4586-2"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Jordan K, Chan A, Gralla RJ et al. 2016 Updated MASCC\/ESMO consensus recommendations: emetic risk classification and evaluation of the emetogenicity of antineoplastic agents. Support Care Cancer. 2017;25(1):271-275. doi: https:\/\/doi.org\/10.1007\/s00520-016-3332-x","DOI":"10.1007\/s00520-016-3332-x"},{"key":"ref6","unstructured":"Petersen PC, Ruhlmann C, Herrstedt J. Kvalme og opkastning induceret af medicinsk kr\u00e6ftbehandling. Ugeskr L\u00e6ger. 2019;181:V02190115."},{"key":"ref7","unstructured":"Ruhlmann C, Petersen PC, Herrstedt J. Forebyggelse og behandling af str\u00e5leterapiinduceret kvalme og opkastning. Ugeskr L\u00e6ger. 2019;181:V02190116."},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Heckroth M, Luckett RT, Moser C et al. Nausea and vomiting in 2021: a comprehensive update. J Clin Gastroenterol. 2021;55(4):279-299. doi: https:\/\/doi.org\/10.1097\/MCG.0000000000001485","DOI":"10.1097\/MCG.0000000000001485"},{"key":"ref9","unstructured":"Feldman M, Friedman LS, Brandt LJ. Nausea and vomiting. I: Sleisenger and Fordtran's gastrointestinal and liver disease, 11th ed. Elsevier, 2021:192."},{"key":"ref10","unstructured":"ApoVision. Sygehusapotekernes \u00f8konomi- lagerstyrings- og logistiksystem. https:\/\/rn.dk\/Til-fagfolk\/Sundhed\/Sundheds-IT\/Nationale-IT-loesninger\/ApoVision (17. jan 20224)."},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Braude D, Soliz T, Crandall C et al. Antiemetics in the ED: a randomized controlled trial comparing 3 common agents. Am J Emerg Med. 2006;24(2):177-82. doi: https:\/\/doi.org\/10.1016\/j.ajem.2005.08.017","DOI":"10.1016\/j.ajem.2005.08.017"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Barrett TW, DiPersio DM, Jenkins CA et al. A randomized, placebo-controlled trial of ondansetron, metoclopramide, and promethazine in adults. Am J Emerg Med. 2011;29(3):247-55. doi: https:\/\/doi.org\/10.1016\/j.ajem.2009.09.028","DOI":"10.1016\/j.ajem.2009.09.028"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Egerton-Warburton D, Meek R, Mee MJ, Braitberg G. Antiemetic use for nausea and vomiting in adult emergency department patients: randomized controlled trial comparing ondansetron, metoclopramide, and placebo. Ann Emerg Med. 2014;64(5):526-532.e1. doi: https:\/\/doi.org\/10.1016\/j.annemergmed.2014.03.017","DOI":"10.1016\/j.annemergmed.2014.03.017"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Braude D, Crandall C. Ondansetron versus promethazine to treat acute undifferentiated nausea in the emergency department: a randomized, double-blind, noninferiority trial. Acad Emerg Med. 2008;15(3):209-15. doi: https:\/\/doi.org\/10.1111\/j.1553-2712.2008.00060.x","DOI":"10.1111\/j.1553-2712.2008.00060.x"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Meek R, Mee MJ, Egerton-Warburton D et al. Randomized placebo-controlled trial of droperidol and ondansetron for adult emergency department patients with nausea. Acad Emerg Med. 2019;26(8):867-877. doi: https:\/\/doi.org\/10.1111\/acem.13650","DOI":"10.1111\/acem.13650"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Philpott L, Clemensen E, Lau GT. Droperidol versus ondansetron for nausea treatment within the emergency department. Emerg Med Australas. 2023;35(4):605-611. doi: https:\/\/doi.org\/10.1111\/1742-6723.14174","DOI":"10.1111\/1742-6723.14174"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Jokar A, Khademhosseini P, Ahmadi K et al. A comparison of metoclopramide and ondansetron efficacy for the prevention of nausea and vomiting in patients suffered from renal colic. Open Access Maced J Med Sci. 2018;6(10):1833-1838. doi: https:\/\/doi.org\/10.3889\/oamjms.2018.302","DOI":"10.3889\/oamjms.2018.302"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Ernst AA, Weiss SJ, Park S et al. Prochlorperazine versus promethazine for uncomplicated nausea and vomiting in the emergency department: a randomized, double-blind clinical trial. Ann Emerg Med. 2000;36(2):89-94. doi: https:\/\/doi.org\/10.1067\/mem.2000.108652","DOI":"10.1067\/mem.2000.108652"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Chae J, Taylor DM, Frauman AG. Tropisetron versus metoclopramide for the treatment of nausea and vomiting in the emergency department: a randomized, double-blinded, clinical trial. Emerg Med Australas. 2011;23(5):554-61. doi: https:\/\/doi.org\/10.1111\/j.1742-6723.2011.01444.x","DOI":"10.1111\/j.1742-6723.2011.01444.x"},{"key":"ref20","unstructured":"Patka J, Wu DT, Abraham P, Sobel RM. Randomized controlled trial of ondansetron vs. prochlorperazine in adults in the emergency department. West J Emerg Med. 2011;12(1):1-5."},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Cham S, Basire M, Kelly AM. Intermediate dose metoclopramide is not more effective than standard dose metoclopramide for patients who present to the emergency department with nausea and vomiting: a pilot study. Emerg Med Australas. 2004;16(3):208-11. doi: https:\/\/doi.org\/10.1111\/j.1742-6723.2004.00588.x","DOI":"10.1111\/j.1742-6723.2004.00588.x"},{"key":"ref22","unstructured":"Sundhedsstyrelsen. Nye anbefalinger for de motilitetsstimulerende, antiemetiske l\u00e6gemidler. Sundhedsstyrelsen, 2015. www.sst.dk\/da\/udgivelser\/2015\/rationel-farmakoterapi-12-2015\/nye-anbefalinger-for-de-motilitetsstimulerende-antiemetiske-laegemidler (19. okt 2023)."},{"key":"ref23","unstructured":"L\u00e6gemiddelstyrelsen. Metoclopramide \u00bbOrifarm\u00ab, tabletter. 2020. https:\/\/produktresume.dk (19. okt 2023)."},{"key":"ref24","unstructured":"L\u00e6gemiddelstyrelsen. Droperidol \u00bbSintetica\u00ab, injektionsv\u00e6ske, opl\u00f8sning. 2023. https:\/\/produktresume.dk (19. okt 2023)."},{"key":"ref25","unstructured":"L\u00e6gemiddelstyrelsen. Domperidon \u00bbAlternova\u00ab, tabletter. 2020. https:\/\/produktresume.dk (19. okt 2023)."},{"key":"ref26","unstructured":"L\u00e6gemiddelstyrelsen. Ondansetron \u00bbOrifarm\u00ab, smeltetabletter. 2023. https:\/\/produktresume.dk (19. okt 2023)."},{"key":"ref27","unstructured":"L\u00e6gemiddelstyrelsen. Prometazin \u00bbActavis\u00ab, filmovertrukne tabletter. 2023. https:\/\/produktresume.dk (19. okt 2023)."},{"key":"ref28","unstructured":"European Medicines Agency. European Medicines Agency recommends changes to the use of metoclopramide. www.ema.europa.eu\/en\/documents\/referral\/metoclopramide-article-31-referral-european-medicines-agency-confirms-changes-use-metoclopramide_en.pdf (19. okt 2023)."}],"container-title":["Ugeskrift for L\u00e6ger"],"original-title":[],"deposited":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T11:47:30Z","timestamp":1718970450000},"score":1,"resource":{"primary":{"URL":"https:\/\/ugeskriftet.dk\/videnskab\/V11230735"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,15]]},"references-count":29,"URL":"https:\/\/doi.org\/10.61409\/v11230735","relation":{},"ISSN":["0041-5782","1603-6824"],"issn-type":[{"value":"0041-5782","type":"print"},{"value":"1603-6824","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,15]]}}}